Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months

Eli Lilly delivered one of the strongest first quarters in big pharma history, indicating robust underlying business performance. However, the stock has pulled back sharply from its February peak, suggesting sentiment and positioning have turned more cautious despite the strong fundamentals.

Analysis

Eli Lilly delivered one of the strongest first quarters in big pharma history, indicating robust underlying business performance. However, the stock has pulled back sharply from its February peak, suggesting sentiment and positioning have turned more cautious despite the strong fundamentals.